Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	1,709
Overall Study	STARTED	Denosumab	1,711
Overall Study	Received Study Drug in the Double-blind Phase	Placebo	1,699
Overall Study	Received Study Drug in the Double-blind Phase	Denosumab	1,700
Overall Study	Continued Into the Open-Label Phase	Placebo	268
Overall Study	Continued Into the Open-Label Phase	Denosumab	3
Overall Study	Safety Analysis Set	Placebo	1,690
Overall Study	Safety Analysis Set	Denosumab	1,709
Overall Study	COMPLETED	Placebo	1,242
Overall Study	COMPLETED	Denosumab	1,362
Overall Study	NOT COMPLETED	Placebo	467
Overall Study	NOT COMPLETED	Denosumab	349

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00556374/flow